Diligence memo · auto-generated · as of July 2, 2026
Gaingels Transcripta Bio LLC
Gaingels Transcripta Bio LLC looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Gaingels Transcripta Bio LLC operates in Biotech / Pharma, based in BURLINGTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Gaingels Transcripta Bio LLC has raised $404K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $404K on 2024-08-13.
Most recent recorded round closed around 2024-08-13.
Valuation (modeled)modeled
Provath models Gaingels Transcripta Bio LLC at approximately $1.7M (range $221K–$5.6M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.81× the median modeled value of Pre-Seed Biotech / Pharma companies in 2022–2024 (28 peers) — value vs value, same stage and era. Within the normal band (81% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 23 mo ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 21% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 14% of those peers.
Closest niche peers: Gaingels Oct Bio LLC, Gaingels Alto Pharmacy LLC, Pyros Pharmaceuticals, Inc., Allander Biotechnologies, Inc., CyMon Bio, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.